You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Mechanosensation by Endothelial PIEZO1 Is Required for Leukocyte Diapedesis

  • Authors: ShengPeng Wang, PhD; Bianbian Wang, MS; Yue Shi, MS; Tanja Möller; Rebekka I. Stegmeyer, MS; Boris Strilic, PhD; Zuyi Yuan, MD, PhD; Changhe Wang, PhD; Nina Wettschureck, MD; Dietmar Vestweber, PhD; Stefan Offermanns, MD
  • CME / ABIM MOC Released: 7/21/2022
  • Valid for credit through: 7/21/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists and other specialists in pathophysiologic mechanisms underlying inflammatory and infectious disease.

The goal of this activity is for learners to be better able to describe how molecular mechanisms underlying the initial interactions between leukocytes and endothelial cells are linked to opening of the endothelial barrier, based on a mouse model.

Upon completion of this activity, participants will:

  1. Describe how low flow and leukocyte-induced intercellular adhesion molecule 1 clustering interact to mechanically activate endothelial PIEZO1, based on a mouse model
  2. Identify the role of PIEZO1 activation in signaling processes leading to opening of the endothelial barrier and leukocyte extravasation, based on a mouse model
  3. Determine pathophysiologic and clinical implications of how molecular mechanisms underlying the initial interactions between leukocytes and endothelial cells are linked to opening of the endothelial barrier, based on a mouse model


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • ShengPeng Wang, PhD

    Department of Cardiology
    First Affiliated Hospital
    Cardiovascular Research Center
    School of Basic Medical Sciences
    Xi'an Jiaotong University
    Xi’an, China
    Max Planck Institute for Heart and Lung Research
    Department of Pharmacology
    Bad Nauheim, Germany

  • Bianbian Wang, MS

    Center for Mitochondrial Biology and Medicine
    School of Life Science and Technology
    Xi’an Jiaotong University
    Xi’an, China

  • Yue Shi, MS

    Department of Cardiology
    First Affiliated Hospital
    Cardiovascular Research Center
    School of Basic Medical Sciences
    Xi'an Jiaotong University
    Xi’an, China
    Max Planck Institute for Heart and Lung Research
    Department of Pharmacology
    Bad Nauheim, Germany

  • Tanja Möller

    Department of Vascular Cell Biology
    Max Planck Institute for Molecular Biomedicine
    Muenster, Germany

  • Rebekka I. Stegmeyer, MS

    Department of Vascular Cell Biology
    Max Planck Institute of Molecular Biomedicine
    Muenster, Germany

  • Boris Strilic, PhD

    Max Planck Institute for Heart and Lung Research
    Department of Pharmacology
    Bad Nauheim, Germany

  • Ting Li, MS

    Department of Cardiology
    First Affiliated Hospital
    Cardiovascular Research Center
    School of Basic Medical Sciences
    Xi'an Jiaotong University
    Xi’an, China

  • Zuyi Yuan, MD, PhD

    Department of Cardiology
    First Affiliated Hospital, Cardiovascular Research Center
    School of Basic Medical Sciences
    Xi'an Jiaotong University
    Xi’an, China

  • Changhe Wang, PhD

    Center for Mitochondrial Biology and Medicine
    School of Life Science and Technology
    Xi’an Jiaotong University
    Xi’an, China

  • Nina Wettschureck, MD

    Max Planck Institute for Heart and Lung Research
    Department of Pharmacology
    Bad Nauheim, Germany
    Center for Molecular Medicine
    Goethe University Frankfurt
    Frankfurt, Germany
    Cardiopulmonary Institute
    Bad Nauheim, Germany
    German Center for Cardiovascular Research (DZHK)
    Rhine-Main site
    Frankfurt and Bad Nauheim, Germany

  • Dietmar Vestweber, PhD

    Department of Vascular Cell Biology
    Max Planck Institute for Molecular Biomedicine
    Muenster, Germany

  • Stefan Offermanns, MD

    Department of Pharmacology
    Max Planck Institute for Heart and Lung Research
    Bad Nauheim, Germany
    Center for Molecular Medicine
    Goethe University Frankfurt
    Frankfurt, Germany
    Cardiopulmonary Institute
    Bad Nauheim, Germany
    German Center for Cardiovascular Research (DZHK)
    Rhine-Main site
    Frankfurt and Bad Nauheim, Germany

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer
    Medscape, LLC

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed the following relevant financial relationships:
    Formerly owned stocks in: AbbVie

Editor

  • Thomas D. Coates

     Associate Editor, Blood

Compliance Reviewer

  • Leigh A. Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance
    Medscape, LLC

    Disclosures

    Disclosure: Leigh A. Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and the American Society of Hematology. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Mechanosensation by Endothelial PIEZO1 Is Required for Leukocyte Diapedesis: Discussion

processing....

Discussion

We report that the mechanosensitive cation channel PIEZO1 plays a critical role in transendothelial migration of leukocytes in vitro and in vivo by integrating low levels of fluid shear stress and mechanical signals induced by clustering of ICAM-1 and thereby mediating increases in [Ca2+]i and a localized opening of the endothelial barrier (Figure 6H). It has been reported that TRPC6 is critically involved in leukocyte-induced increases in endothelial [Ca2+]i during leukocyte transendothelial migration.[19] In expression analyses, we were not able to observe expression of TRPC6 in endothelial cells (supplemental Figure 1J). Nevertheless, it could well be that both PIEZO1 and TRPC6 operate in parallel under in vivo conditions or that PIEZO1 is involved in the initiation of leukocyte extravasation by sensing both flow and leukocyte adhesion, whereas TRPC6 mediates increases in [Ca2+]i mainly at later stages of diapedesis.

ICAM-1 is a central endothelial adhesion receptor that functions as a ligand for β2 integrins on leukocytes and promotes leukocyte spreading, migration, and transmigration.[29,42] Engagement of ICAM-1 leads to the clustering of ICAM-1 molecules and its redistribution into ring-like structures around adherent leukocytes, which is a requirement for efficient downstream signaling.[43,44] ICAM-1 clustering induces cytoskeletal changes such as actin polymerization, MLC phosphorylation, and actomyosin contractility, which promote junctional opening.[18,31,42,45] ICAM-1 also promotes increase in [Ca2+]i levels,[13,46] which has been shown to lead to activation of SRC via protein kinase C.[15] ICAM-1–mediated activation of SRC and PYK2 has been shown to be required for VE-cadherin–dependent leukocyte transendothelial migration.[30] This involves direct phosphorylation of VE-cadherin[30,47,48] and indirect regulation of VE-cadherin through VE-PTP[49] or by phosphorylation of β-catenin.[50] How ICAM-1 clustering induces activation of these downstream signaling events resulting in junctional opening and transendothelial migration is poorly understood. Our data indicate that downstream signaling through ICAM-1 requires coactivation of PIEZO1 by fluid shear stress and ICAM-1–induced reorganization of the cortical cytoskeleton.

Various mechanical stimuli acting on cellular membranes have been shown to be able to activate PIEZO1. These include exposure to fluid shear stress, mechanical indentation of the cell surface, cell migration, compression of the cell membrane, or forces generated at the cell–cell or cell–matrix interface.[21,51] Our data show that low-level fluid shear stress and interaction of leukocytes with the endothelial surface act in a synergistic manner to activate endothelial PIEZO1 and to initiate leukocyte transendothelial migration. In postcapillary venules, the place where leukocyte extravasation mainly takes place, the shear stress exerted by the flowing blood is relatively low at about 1 to 2 dynes/cm,[2,52,53] a shear rate hardly able to induce PIEZO1-mediated signaling.[27,28] Consistent with this, we saw only very small increases in [Ca2+]i and no significant increase in the phosphorylation of PYK2, SRC, or MLC in response to fluid shear stress of 1.2 dynes/cm2. Similarly, when ICAM-1 clustering was induced in TNFα-pretreated endothelial cells by PMNs or anti–ICAM-1 antibodies, only small increases in [Ca2+]i and phosphorylation of PYK2, SRC, and MLC could be observed, which were further reduced after suppression of Piezo1 expression. However, when endothelial ICAM-1 clustering was induced while exposing cells to low flow, downstream signaling was strongly activated, and this effect was inhibited by knockdown of PIEZO1. This raised the question as to how ICAM-1 clustering promotes PIEZO1 activation. Both ICAM-1 clustering and adhesion of leukocytes to endothelial cells have been shown to induce stiffening of the endothelial surface and to induce traction stress.[31–34,54] These endothelial responses are caused by increased actin polymerization and actomyosin contractility of the cortical cytoskeleton, which lead to increased cortical tension[40,41] and require recruitment of the actin adapter proteins a-actinin-4 and cortactin.[31,37] Because the plasma membrane and the underlying cortical cytoskeleton are closely interconnected,[40,41] changes in the actomyosin cortical tension directly affect plasma membrane tension[41] and therefore are likely to regulate PIEZO1 activity. Consistent with this, we found that inhibition of actin polymerization and myosin activity and siRNA-mediated knockdown of α-actinin-4 and cortactin blocked ICAM-1–mediated increases in membrane tension and PIEZO1-dependent downstream signaling required for leukocyte transendothelial migration. We therefore also think that it is the combined effect of low flow and leukocyte-induced ICAM-1 clustering on plasma membrane tension that induces PIEZO1 activation. This is consistent with a series of biophysical studies showing that changes in plasma membrane tension are sufficient to regulate the open probability of PIEZO1 and that no intra- or extracellular interactions are required.[23–25] However, we cannot exclude that additional mechanisms are involved. For instance, it has recently been suggested that Piezo1 can be linked to the actin cytoskeleton through members of the cadherin family including VE-cadherin,[55] and this mechanism may contribute to Piezo1 activation induced by ICAM-1 clustering and subsequent actin polymerization.

Recent data indicate that changes in plasma membrane tension are restricted to subcellular domains of endothelial cells as local increases in membrane tension lead only to local activation of mechanosensitive ion channels such as PIEZO1.[56] The finding that leukocyte-induced endothelial downstream signaling and diapedesis require PIEZO1 and flow is consistent with earlier observations, which showed that fluid shear stress promotes transendothelial leukocyte migration.[57–60] Our data identify a novel synergism of local hemodynamic forces and initial endothelial leukocyte adhesion to induce plasma membrane tension and endothelial signaling events that promote leukocyte extravasation. The discovery of a novel mechanosensing and mechanosignaling process required for the initial phase of leukocyte diapedesis may also lead to new anti-inflammatory therapeutic approaches.